Daily Summary
A former top FDA vaccine official accused Robert F. Kennedy Jr.'s team of fabricating data to bolster anti-vaccine claims and weaken regulatory oversight, including pushing for weakened scrutiny of experimental treatments, while also criticizing delays in COVID vaccine approvals. Meanwhile, China’s imposition of steep retaliatory tariffs on U.S. imports in response to Trump-era trade policies triggered a severe global market downturn, with major U.S. indices and international markets suffering significant losses. Both developments have heightened concerns over public health governance and global economic stability amidst escalating political and regulatory tensions.
Stock Market Suffers Worst Week Since 2020 as China Retaliates with 34% Tariff
Global markets plunged after China imposed a 34% retaliatory tariff on U.S. imports, deepening fears of a global recession amid rising trade tensions and policy battles.
Ousted Vaccine Official Claims Kennedy’s Team Sought Nonexistent Data to Back Anti-Science Claims
Peter Marks, the former FDA vaccine chief, claims that Robert F. Kennedy Jr.’s team sought non-existent data to support anti-vaccine claims, even as broader federal health agency restructuring unfolds and delays impact vaccine approvals.